DPPC
Venus team is working on target-based drug delivery for cancer treatment. The Company has designed a platform technology with a novel concept of triple conjugate i.e., Drug-Protein-Polymer-Conjugate (DPPC) for the purpose. Based on the specificity of the target organ, various components of DPPC can be rationally selected.
- Highly target specific and selective drug delivery system to a defined population of cells/organ(s) for chronic disease therapy like cancer.
- Minimized uptake of an active drug, by normal cells and enhances the influx and retention of the drug in target cells/ tissues/ organs.
- It provides a pharmaceutical formulation that is administered as a single unit dose through the IV route of the administration having better patient compliance.
- Lower dose and reduced frequency of the administration of a drug in comparison to individual use of the drug or known drug-polymer or known protein-polymer conjugate.
- Improved availability of the drug molecule at the target site and reduction in side effects due to targeted delivery and sustained release.
Discover our areas of work
Formulation & Development
Formulation development is the core (sanctum sanctorum) art and science of preparation.
STN
With an aim to preserve the life of existing antibiotics and to guide better clinical decisions
SPIPC
Venus has developed a super porous interpolymeric complex based on physical charge distribution phenomena